Therapeutic allogeneic lymphocytes
- Generic Name
- Therapeutic allogeneic lymphocytes
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
Phase 1
Completed
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Atypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeChildhood Myelodysplastic SyndromesChronic Myelogenous Leukemia, BCR-ABL1 PositiveDisseminated NeuroblastomaMalignant Neoplasm
- Interventions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2013-03-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT00060372
- Locations
- 🇺🇸
Scripps Clinic - La Jolla, La Jolla, California, United States
🇺🇸University of California San Diego, La Jolla, California, United States
🇺🇸Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath